[Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)].
Heuck
A
A
Institut für Radiologische Diagnostik, Klinikum Grosshadern der Universität.
Reiser
M
M
D000818:Animals; D003287:Contrast Media / Q000009:adverse effects* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000009:adverse effects* / Q000493:pharmacokinetics; D006571:Heterocyclic Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D007677:Kidney Function Tests; D008279:Magnetic Resonance Imaging; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics; D051437:Renal Insufficiency / Q000097:blood / Q000139:chemically induced*
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA
Nephrotoxizität von Konstrastmitteln bei Magnetresonanztomographie (MRT).